Data: 01 de Julho de 2023
Horário: 08:00 – 18:00
Formato: 100% ONLINE
Apresentação:
O Congresso Anual da Sociedade Americana de Oncologia Clínica (ASCO) traz inúmeras novidades com impacto direto na prática da oncologia. O objetivo desse evento é discutir os principais resultados apresentados em cada área, e trazê-los para o dia a dia do cuidado oncológico.
Objetivos:
Revisitar os principais trabalhos apresentados no Congresso Anual da ASCO, buscando traduzir e contextualizar seu significado, sempre de forma crítica e com discussões envolvendo nossas lideranças em oncologia
Diferenciais:
Exploração das novidades, revisão e uma contextualização das novas descobertas apresentadas no Congresso Anual da Sociedade Americana de Oncologia Clínica (ASCO), que é um dos mais importantes do mundo na área de oncologia.
Público-alvo:
Oncologistas clínicos, cirurgiões, rádio-oncologistas e médicos residentes.
Certificados: O certificado será liberado em até 15 dias após a realização do evento, na plataforma de inscrições.
| Programação: Sábado, 01 de Julho de 2023
*Programação sujeita a alterações e confirmações de convidados |
|
| 08:00 - 08:10 |
Abertura Palestrante: Artur Katz |
|
Mama Coordenador: Artur Katz |
|
| 08:10 - 08:30 |
Dados da ASCO* – Parte 1 Palestrante: Marina Sahade - Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial. -Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC). - 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). - Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. |
| 08:30 - 08:50 |
Dados da ASCO* – Parte 2 Palestrante: Andrea Shimada - Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). - Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. - Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. - Topical diclofenac in prevention of capecitabine associated HFS in patients with breast cancer: An exploratory subgroup analysis of the D-ToRCH study. |
| 08:50 - 09:10 |
Resultados em perspectiva Palestrante: Carlos Henrique dos Anjos |
| 09:10 - 09:20 |
Discussão e Q&A Debatedores: Marina Sahade, Andrea Shimada e Carlos Henrique dos Anjos |
|
Neuro Coordenador: Olavo Feher |
|
| 09:20 - 09:40 |
Dados da ASCO* Palestrante: Gustavo Matos LBA1 - INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. abstr2008 - Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study. abstr2001 - Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. abstr2002 - Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma. |
| 09:40 - 10:00 |
Resultados em perspectiva Palestrante: Felipe Canedo |
| 10:00 - 10:10 |
Discussão e Q&A Debatedores: Adriana Barrichelo e Felipe Canedo |
| Simpósio Satélite Daiichi Sankyo | |
| 10:10 - 11:00 |
Prática clínica com T-DXd: Análise integrada da paciente idosa Palestrante: Andrea Shimada |
|
Tumores GU Coordenador: Diogo Bastos |
|
| 11:00 - 11:20 |
Dados da ASCO* – Parte 1 Palestrante: David Muniz Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design. Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials. Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations. Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne. |
| 11:20 - 11:40 |
Dados da ASCO* – Parte 2 Palestrante: Gabriel Clemente Abstr 4502: Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) LBA4501: Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426 LBA4500: Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. Abstr4508: SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. LBA4507: Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. LBA4619: Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). Abstr 4504: Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study. |
| 11:40 - 12:00 |
Resultados em perspectiva Palestrante: Daniel Girardi |
| 12:00 - 12:10 |
Discussão e Q&A Debatedores: David Muniz, Gabriel Clemente e Daniel Girardi |
| Simpósio Satélite Novartis | |
| 12:10 - 13:00 |
Tratamento adjuvante do câncer de mama RH+/HER2- em 2023: Novas perspectivas com inibidores de CDK4/6 e resultados do estudo Natalee Palestrante: Rudinei Linck |
|
Tumores GI Coordenador: Frederico Costa |
|
| 13:00 - 13:20 | Dados da ASCO* – Parte 1 Palestrante: Allan Pereira Abs 4000 - ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer. LBA4005 - Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). ABS 4006 - Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. |
| 13:20 - 13:40 |
Dados da ASCO* – Parte 2 PROSPECT, PRODIGE 23 e DESTINY-CRC 02 Palestrante: Tulio Pfiffer |
| 13:40 - 14:00 |
Resultados em perspectiva Palestrante: Fernanda Caparelli |
| 14:00 - 14:10 |
Discussão e Q&A Debatedores: Allan Pereira, Tulio Pfiffer e Fernanda Caparelli |
|
Pulmão e Cabeça/Pescoço Coordenador: Gilberto Castro |
|
| 14:10 - 14:40 |
Dados da ASCO* – Parte 1 Palestrante: João Vitor Alessi Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. (Abstract 8501) Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). (LBA3) KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. (LBA100) A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study. (LBA9009) IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial. (Abstract 8505) Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. (LBA9000) Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.(Abstract 9002) Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study. (LBA9005) |
| 14:40 - 14:50 |
Dados da ASCO* – Parte 2 Palestrangte: Breno Jeha Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. (Abstract 6000) Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. (Abstract 6001) PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). (Abstract 6002) Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001). (LBA6004) Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.(Abstract 6003) |
| 14:50 - 15:10 |
Resultados em perspectiva Palestrante: Guilherme Harada |
| 15:10 - 15:20 |
Discussão e Q&A Debatedores: Breno Jeha, João Vitor Alessi e Guilherme Harada |
| 15:20 - 15:40 | Intervalo |
|
Melanoma/Sarcoma Coordenador: Rodrigo Munhoz |
|
| 15:40 - 16:00 |
Dados da ASCO* – Parte 1 Palestrante: Luiza Dib Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis. Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. |
| 16:00 - 16:20 |
Dados da ASCO* – Parte 2 Palestrante: Tatiana Strava Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial—The MATISSE trial. The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo. A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902). |
| 16:20 - 16:40 |
Resultados em perspectiva Palestrante: Rodrigo Munhoz |
| 16:40 - 16:50 |
Discussão e Q&A Debatedores: Luiza Dib, Tatiana Strava e Rodrigo Munhoz |
|
Tumores ginecológicos Coordenadora: Rudinei Linck |
|
| 16:50 - 17:10 |
Dados da ASCO* – Parte 1 Palestrante: Fernanda Moura LBA5511 - An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE). abstr5500 - KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. abstr5516 - Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. |
| 17:10 - 17:30 |
Dados da ASCO* – Parte 2 Palestrante: Daniele Assad LBA5506 - Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. LBA5507 - Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. |
| 17:30 - 17:50 |
Resultados em perspectiva Palestrante: Rudinei Linck |
| 17:50 - 18:00 |
Discussão e Q&A Debatedores: Fernanda Moura, Daniela Assad e Rudinei Linck |